{"title":"[Edible cannabis: Safe food? About a series of 5 cases].","authors":"Sandra Thorigné, Véronique Ferey, Elodie Saussereau, Sabrina Cherki, Reynald Le Boisselier","doi":"10.1016/j.therap.2025.11.007","DOIUrl":"https://doi.org/10.1016/j.therap.2025.11.007","url":null,"abstract":"","PeriodicalId":23147,"journal":{"name":"Therapie","volume":" ","pages":""},"PeriodicalIF":1.8,"publicationDate":"2025-11-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145701870","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-11-25DOI: 10.1016/j.therap.2025.11.006
Diane Le Bouëdec, Romain Pelletier, François Bénézit, Raphaël Pangui, Isabelle Morel, Thomas Gicquel
Chemsex refers to the intentional use of psychoactive substances to enhance sexual expériences. It often involves prolonged sexual sessions, multiple partners, and the use of drugs such as GHB, synthetic cathinones, and erectile dysfunction medications. Prevalence estimates vary widely across studies, ranging from 9 to 21% in Europe, reflecting heterogeneity in definitions and populations studied. This practice can be associated to serious health risks, including substance addiction, psychiatric disorders, and increased rates of sexually transmitted infections (STIs), notably HIV and hepatitis C. Intravenous drug use during sex ("slamming") carries particularly high risks. Despite its initial emergence in men who have sex with men (MSM) communities, chemsex is also reported among heterosexual and transgender populations. Effective responses require non-judgmental, multidisciplinary support, combining harm reduction, mental health care, and STI prevention. Healthcare professionals must be trained to recognize and address chemsex-related issues. Further research is needed to better define the phenomenon and inform public health strategies. This article provides a brief review of the characteristics, epidemiology, and potential addictive, infectious, and psychological consequences of chemsex.
{"title":"Chemsex, drugs and consequences: A short review.","authors":"Diane Le Bouëdec, Romain Pelletier, François Bénézit, Raphaël Pangui, Isabelle Morel, Thomas Gicquel","doi":"10.1016/j.therap.2025.11.006","DOIUrl":"https://doi.org/10.1016/j.therap.2025.11.006","url":null,"abstract":"<p><p>Chemsex refers to the intentional use of psychoactive substances to enhance sexual expériences. It often involves prolonged sexual sessions, multiple partners, and the use of drugs such as GHB, synthetic cathinones, and erectile dysfunction medications. Prevalence estimates vary widely across studies, ranging from 9 to 21% in Europe, reflecting heterogeneity in definitions and populations studied. This practice can be associated to serious health risks, including substance addiction, psychiatric disorders, and increased rates of sexually transmitted infections (STIs), notably HIV and hepatitis C. Intravenous drug use during sex (\"slamming\") carries particularly high risks. Despite its initial emergence in men who have sex with men (MSM) communities, chemsex is also reported among heterosexual and transgender populations. Effective responses require non-judgmental, multidisciplinary support, combining harm reduction, mental health care, and STI prevention. Healthcare professionals must be trained to recognize and address chemsex-related issues. Further research is needed to better define the phenomenon and inform public health strategies. This article provides a brief review of the characteristics, epidemiology, and potential addictive, infectious, and psychological consequences of chemsex.</p>","PeriodicalId":23147,"journal":{"name":"Therapie","volume":" ","pages":""},"PeriodicalIF":1.8,"publicationDate":"2025-11-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145744409","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-11-20DOI: 10.1016/j.therap.2025.11.004
Jean-Louis Montastruc
Background: Gender differences were reported in Parkinson's disease as well as in drug effects in general.
Objective: The study was performed to investigate putative gender differences in levodopa-related adverse drug reactions (ADRs).
Methods: Using Vigibase®, the global pharmacovigilance database, all ADRs reports with levodopa between 01/01/2000 and 31/12/2024 in adults were included. The main levodopa (motor and non-motor) ADRs were compared between women and men. Results are presented as reporting odds ratios (ROR) with their 95% confidence interval.
Results: Among 2887 ADRs with levodopa, the reporting risk in women was significantly higher for dyskinesia (ROR=1.31 [1.00-1.71]), dystonia (1.41 [1.03-1.93]), nausea-vomiting (2.08 [1.45-2.99]), and significantly lower for hypersexuality (0.10 [0.02-0.42]), dopamine dysregulation syndrome (0.32 [0.14-0.73]) pathological gambling (0.33 [0.14-0.76]) and all ADRs in general (0.48 [0.45-0.52]), with no difference for other ADRs.
Conclusion: This study shows gender-related differences for not only motor (dyskinesia, dystonia) but also non-motor levodopa ADRs.
{"title":"Are there gender differences in adverse drug reactions to levodopa? A real-world safety comparison in the global pharmacovigilance database.","authors":"Jean-Louis Montastruc","doi":"10.1016/j.therap.2025.11.004","DOIUrl":"https://doi.org/10.1016/j.therap.2025.11.004","url":null,"abstract":"<p><strong>Background: </strong>Gender differences were reported in Parkinson's disease as well as in drug effects in general.</p><p><strong>Objective: </strong>The study was performed to investigate putative gender differences in levodopa-related adverse drug reactions (ADRs).</p><p><strong>Methods: </strong>Using Vigibase®, the global pharmacovigilance database, all ADRs reports with levodopa between 01/01/2000 and 31/12/2024 in adults were included. The main levodopa (motor and non-motor) ADRs were compared between women and men. Results are presented as reporting odds ratios (ROR) with their 95% confidence interval.</p><p><strong>Results: </strong>Among 2887 ADRs with levodopa, the reporting risk in women was significantly higher for dyskinesia (ROR=1.31 [1.00-1.71]), dystonia (1.41 [1.03-1.93]), nausea-vomiting (2.08 [1.45-2.99]), and significantly lower for hypersexuality (0.10 [0.02-0.42]), dopamine dysregulation syndrome (0.32 [0.14-0.73]) pathological gambling (0.33 [0.14-0.76]) and all ADRs in general (0.48 [0.45-0.52]), with no difference for other ADRs.</p><p><strong>Conclusion: </strong>This study shows gender-related differences for not only motor (dyskinesia, dystonia) but also non-motor levodopa ADRs.</p>","PeriodicalId":23147,"journal":{"name":"Therapie","volume":" ","pages":""},"PeriodicalIF":1.8,"publicationDate":"2025-11-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145726096","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-11-20DOI: 10.1016/j.therap.2025.11.005
Gwendal Dubois, Charles Khouri, Christophe Seinturier, Sophie Blaise
{"title":"Cerebral air embolism induced by polidocanol foam sclerotherapy in chronic venous disease: A case report.","authors":"Gwendal Dubois, Charles Khouri, Christophe Seinturier, Sophie Blaise","doi":"10.1016/j.therap.2025.11.005","DOIUrl":"https://doi.org/10.1016/j.therap.2025.11.005","url":null,"abstract":"","PeriodicalId":23147,"journal":{"name":"Therapie","volume":" ","pages":""},"PeriodicalIF":1.8,"publicationDate":"2025-11-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145744363","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-11-20DOI: 10.1016/j.therap.2025.11.003
Omar Masrour, Roya Nili Asgari, Anne Charpentier, Olivier Sanchez, Jean Pastre
{"title":"Hydroxyurea-induced severe interstitial pneumonitis: A case report.","authors":"Omar Masrour, Roya Nili Asgari, Anne Charpentier, Olivier Sanchez, Jean Pastre","doi":"10.1016/j.therap.2025.11.003","DOIUrl":"https://doi.org/10.1016/j.therap.2025.11.003","url":null,"abstract":"","PeriodicalId":23147,"journal":{"name":"Therapie","volume":" ","pages":""},"PeriodicalIF":1.8,"publicationDate":"2025-11-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145679010","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Background: Physicochemical incompatibilities of parenteral drugs are frequently studied and reported, but are rarely documented for liquid oral drugs. However, in clinical practices, nurses may perform mixtures of several liquid oral formulations. Although such practices are not recommended, there is a lack of scientific evidence to support this statement.
Objective: We aimed to study potential incompatibilities of the most dispensed commercial liquid oral formulations in a psychiatric ward.
Methods: First, a bibliographic analysis was performed. Then, 1:1 mixtures of one commercial liquid specialty and tap water and 1:1:1 mixtures of two commercial formulations and water were realized and controlled both visually and analytically. When a precipitate was formed, the mixture was considered incompatible.
Results: A table of oral liquid drug incompatibilities was compiled, and the need for pharmaceutical expertise on this subject was discussed.
Conclusion: This work is the first report of oral liquid drugs' physicochemical incompatibilities and can lead to an improvement in clinical practices.
{"title":"Mixtures and dilutions of commercial solutions for oral drops: What happens in these cocktails?","authors":"Caroline Castera-Ducros, Romain Paoli-Lombardo, Ikram Zaddam, Cyril Fersing, Charleric Bornet, Patrice Vanelle, Pascal Rathelot, Christophe Curti","doi":"10.1016/j.therap.2025.11.002","DOIUrl":"https://doi.org/10.1016/j.therap.2025.11.002","url":null,"abstract":"<p><strong>Background: </strong>Physicochemical incompatibilities of parenteral drugs are frequently studied and reported, but are rarely documented for liquid oral drugs. However, in clinical practices, nurses may perform mixtures of several liquid oral formulations. Although such practices are not recommended, there is a lack of scientific evidence to support this statement.</p><p><strong>Objective: </strong>We aimed to study potential incompatibilities of the most dispensed commercial liquid oral formulations in a psychiatric ward.</p><p><strong>Methods: </strong>First, a bibliographic analysis was performed. Then, 1:1 mixtures of one commercial liquid specialty and tap water and 1:1:1 mixtures of two commercial formulations and water were realized and controlled both visually and analytically. When a precipitate was formed, the mixture was considered incompatible.</p><p><strong>Results: </strong>A table of oral liquid drug incompatibilities was compiled, and the need for pharmaceutical expertise on this subject was discussed.</p><p><strong>Conclusion: </strong>This work is the first report of oral liquid drugs' physicochemical incompatibilities and can lead to an improvement in clinical practices.</p>","PeriodicalId":23147,"journal":{"name":"Therapie","volume":" ","pages":""},"PeriodicalIF":1.8,"publicationDate":"2025-11-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145669233","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-11-07DOI: 10.1016/j.therap.2025.11.001
Quentin Tourdot, Margot Lestienne, Paul Mathieu, Thomas Risdorfer De Issdentzi, Coralie Bourzeix, Laura Jaubert, Hélène Donnadieu, Céline Eiden, Hélène Peyrière
{"title":"Intranasal abuse of buspirone: Cases serie.","authors":"Quentin Tourdot, Margot Lestienne, Paul Mathieu, Thomas Risdorfer De Issdentzi, Coralie Bourzeix, Laura Jaubert, Hélène Donnadieu, Céline Eiden, Hélène Peyrière","doi":"10.1016/j.therap.2025.11.001","DOIUrl":"https://doi.org/10.1016/j.therap.2025.11.001","url":null,"abstract":"","PeriodicalId":23147,"journal":{"name":"Therapie","volume":" ","pages":""},"PeriodicalIF":1.8,"publicationDate":"2025-11-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145565499","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-11-01DOI: 10.1016/j.therap.2025.10.002
Florian Lemaitre , Caroline Monchaud , Matthieu Grégoire , Romain Guilhaumou , Françoise Goirand , groupe de travail « Suivi thérapeutique pharmacologique et personnalisation des traitements de la Société française de pharmacologie et de thérapeutique »
En 2024, le groupe de travail « Suivi thérapeutique pharmacologique et personnalisation des traitements de la Société française de pharmacologie et de thérapeutique » a élaboré un livre blanc dont l’objectif est de présenter l’état des lieux de la sous-discipline de la pharmacologie biologique, de décrire les compétences attendues pour exercer le métier de pharmacologue biologiste, de définir le périmètre de l’activité professionnelle, d’identifier les forces et les points d’amélioration actuels de la sous-discipline dans l’objectif final de proposer les évolutions du métier de pharmacologue biologiste. Ce document se compose de plusieurs parties : un préambule visant à rappeler le panorama de la pharmacologie biologique en France ; un état des lieux rappelant ce qu’est un pharmacologue biologiste, ses missions, les forces et faiblesses de la profession et les pré-requis en termes de formation ; un référentiel de compétences du pharmacologue biologiste et enfin les perspectives et nouvelles missions du pharmacologue biologiste. Ce document a pour vocation de servir de référentiel, d’aider à définir la profession de pharmacologue biologiste et de structurer la discipline afin de pouvoir la faire évoluer vers une profession d’interface entre biologie et clinique.
In 2024, the therapeutic drug monitoring and treatment personalization working group of the Société française de pharmacologie et de thérapeutique (French Society of Pharmacology and Therapeutics) drew up a white paper, the aim of which is to present the current state of the biological pharmacology discipline, describe the skills required to exercise the profession, define the scope of professional activity, identify the discipline's current strengths and areas for improvement, with the ultimate aim of proposing changes to the profession of biological pharmacologist. This document is divided into several parts: a preamble outlining the panorama of biological pharmacology in France; a review of the current situation, outlining what a pharmacological biologist is, his or her missions, the strengths and weaknesses of the profession, and the prerequisites in terms of training; a reference framework of competencies for the pharmacological biologist; and, finally, the prospects and new missions of the pharmacological biologist. The purpose of this document is to serve as a term of reference, to help define the profession of pharmacological biologist, and to structure the discipline so that it can evolve into a profession at the interface between biology and the clinic.
2024年,工作组后续«药理治疗及个体化治疗的法国社会药理学与治疗学»起草了一份白皮书,其目标是现状介绍生物药理学的挑战性,期望为从事职业技能描述药理学家、生物学家大院界定职业活动,确定该亚学科当前的优势和改进点，最终目标是提出生物药理学专业的发展。该文件由几个部分组成：序言部分旨在回顾法国生物药理学的概况；概述生物药理学家是什么，他的任务，这个职业的优势和劣势，以及培训的先决条件；生物药理学家技能的参考，以及生物药理学家的观点和新任务。本文件的目的是作为一个参考点，帮助定义生物药理学专业，并组织该学科，使其发展成为生物学和临床之间的接口专业。2024 In the治疗药物监测和治疗,personalization working group of the法国社会药理学与治疗学》(French Society of Pharmacology Therapeutics) drew up the aim of which is to a white paper,此证the current state of the生物学科Pharmacology),描述the skills to演习为他的职业、define the scope of professional活动,查明the discipline’s current集中优势区for improvement,最终目标是对生物药理学专业提出改变。本文分为几个部分：初步概述了法国生物药理学的概况；对当前情况的回顾，概述药理学生物学家是什么，他或她的任务，专业的优势和劣势，以及培训方面的先决条件；药理生物学家的职权参考框架；最后，药理学生物学家的前景和新任务。本文的目的是作为一个参考术语，帮助定义药理学生物学家的职业，并构建这一学科，使其能够在生物学和临床之间的接口上发展成一个专业。
{"title":"Livre blanc de la pharmacologie biologique","authors":"Florian Lemaitre , Caroline Monchaud , Matthieu Grégoire , Romain Guilhaumou , Françoise Goirand , groupe de travail « Suivi thérapeutique pharmacologique et personnalisation des traitements de la Société française de pharmacologie et de thérapeutique »","doi":"10.1016/j.therap.2025.10.002","DOIUrl":"10.1016/j.therap.2025.10.002","url":null,"abstract":"<div><div>En 2024, le groupe de travail « Suivi thérapeutique pharmacologique et personnalisation des traitements de la Société française de pharmacologie et de thérapeutique » a élaboré un livre blanc dont l’objectif est de présenter l’état des lieux de la sous-discipline de la pharmacologie biologique, de décrire les compétences attendues pour exercer le métier de pharmacologue biologiste, de définir le périmètre de l’activité professionnelle, d’identifier les forces et les points d’amélioration actuels de la sous-discipline dans l’objectif final de proposer les évolutions du métier de pharmacologue biologiste. Ce document se compose de plusieurs parties : un préambule visant à rappeler le panorama de la pharmacologie biologique en France ; un état des lieux rappelant ce qu’est un pharmacologue biologiste, ses missions, les forces et faiblesses de la profession et les pré-requis en termes de formation ; un référentiel de compétences du pharmacologue biologiste et enfin les perspectives et nouvelles missions du pharmacologue biologiste. Ce document a pour vocation de servir de référentiel, d’aider à définir la profession de pharmacologue biologiste et de structurer la discipline afin de pouvoir la faire évoluer vers une profession d’interface entre biologie et clinique.</div></div><div><div>In 2024, the therapeutic drug monitoring and treatment personalization working group of the Société française de pharmacologie et de thérapeutique (French Society of Pharmacology and Therapeutics) drew up a white paper, the aim of which is to present the current state of the biological pharmacology discipline, describe the skills required to exercise the profession, define the scope of professional activity, identify the discipline's current strengths and areas for improvement, with the ultimate aim of proposing changes to the profession of biological pharmacologist. This document is divided into several parts: a preamble outlining the panorama of biological pharmacology in France; a review of the current situation, outlining what a pharmacological biologist is, his or her missions, the strengths and weaknesses of the profession, and the prerequisites in terms of training; a reference framework of competencies for the pharmacological biologist; and, finally, the prospects and new missions of the pharmacological biologist. The purpose of this document is to serve as a term of reference, to help define the profession of pharmacological biologist, and to structure the discipline so that it can evolve into a profession at the interface between biology and the clinic.</div></div>","PeriodicalId":23147,"journal":{"name":"Therapie","volume":"80 6","pages":"Pages 681-688"},"PeriodicalIF":1.8,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145610242","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
<div><h3>Introduction</h3><div>Les chirurgiens-dentistes, dans l’exercice de leur profession, assument la responsabilité tant du bénéfice que du risque associé aux médicaments qu’ils prescrivent. Leur code de déontologie, leur accorde une liberté dans leurs prescriptions tout en les incitant à limiter leurs interventions aux seuls besoins nécessaires à la qualité et à l’efficacité des soins. De plus, les chirurgiens-dentistes sont également confrontés aux effets indésirables odontologiques résultant de médicaments qu’ils n’ont pas eux-mêmes prescrits. Une étude basée sur l’analyse des cas enregistrés sur dix ans dans la base nationale de pharmacovigilance (BNPV) se révèle pertinente pour dresser un état des lieux de la déclaration de pharmacovigilance émanant des chirurgiens-dentistes.</div></div><div><h3>Méthodes</h3><div>Nous avons réalisé une analyse rétrospective des cas enregistrés dans la BNPV déclarés par les chirurgiens-dentistes entre le 01/01/2013 et le 31/12/2023.</div></div><div><h3>Résultats</h3><div>Sur une période de 10 ans, 509 signalements ont été rapportés, représentant 0,06 % de l’ensemble des cas enregistrés. Ces signalements ont été répartis en trois groupes principaux. Parmi ces 509 déclarations, 24,8 % sont des cas associés à des médicaments utilisés dans le domaine de l’odontologie, comme les anti-inflammatoires, les antibiotiques, les anesthésiques locaux ou encore les antiseptiques locaux ; 35,2 % sont des cas d’effets indésirables odontologiques comme les ostéonécroses de la mâchoire, les hypertrophies gingivales et les ulcérations buccales. Enfin, 28,3 % des cas concernent des déclarations d’effets indésirables en lien avec la vaccination <em>coronavirus disease</em> 2019 (COVID-19) débutée fin décembre 2020.</div></div><div><h3>Conclusion</h3><div>Le faible taux de déclarations de pharmacovigilance par les chirurgiens-dentistes en France au cours des dix dernières années met en évidence un problème de sous-déclaration des effets indésirables dans la pratique dentaire. Les données récentes de la littérature soulignent l’importance de la déclaration de pharmacovigilance dans le domaine de l’odontologie, notamment sur les effets odontologiques.</div></div><div><h3>Introduction</h3><div>Dentists, in their practice, bear responsibility for the benefits and the risks associated with the medications they prescribe. Their code of ethics grants them the freedom to prescribe while encouraging them to limit their interventions to what is strictly necessary for the quality and effectiveness of care. Furthermore, dentists also face ontological adverse effects resulting from medications they did not personally prescribe. A study based on the analysis of cases recorded over ten years in the national pharmacovigilance database (BNPV) is relevant for assessing the current state of pharmacovigilance reports submitted by dentists.</div></div><div><h3>Methods</h3><div>We conducted a retrospective analysis of the cases recorded in the BNP
{"title":"Analyse de la déclaration de pharmacovigilance par les chirurgiens-dentistes en France : bilan des 10 dernières années","authors":"Antonin Vagnet , Hélène Peyrouzet , Viktoryia Prontskus , Corinne Guihard , Lucie Vettoretti , Marie Blanche Valnet Rabier","doi":"10.1016/j.therap.2025.02.011","DOIUrl":"10.1016/j.therap.2025.02.011","url":null,"abstract":"<div><h3>Introduction</h3><div>Les chirurgiens-dentistes, dans l’exercice de leur profession, assument la responsabilité tant du bénéfice que du risque associé aux médicaments qu’ils prescrivent. Leur code de déontologie, leur accorde une liberté dans leurs prescriptions tout en les incitant à limiter leurs interventions aux seuls besoins nécessaires à la qualité et à l’efficacité des soins. De plus, les chirurgiens-dentistes sont également confrontés aux effets indésirables odontologiques résultant de médicaments qu’ils n’ont pas eux-mêmes prescrits. Une étude basée sur l’analyse des cas enregistrés sur dix ans dans la base nationale de pharmacovigilance (BNPV) se révèle pertinente pour dresser un état des lieux de la déclaration de pharmacovigilance émanant des chirurgiens-dentistes.</div></div><div><h3>Méthodes</h3><div>Nous avons réalisé une analyse rétrospective des cas enregistrés dans la BNPV déclarés par les chirurgiens-dentistes entre le 01/01/2013 et le 31/12/2023.</div></div><div><h3>Résultats</h3><div>Sur une période de 10 ans, 509 signalements ont été rapportés, représentant 0,06 % de l’ensemble des cas enregistrés. Ces signalements ont été répartis en trois groupes principaux. Parmi ces 509 déclarations, 24,8 % sont des cas associés à des médicaments utilisés dans le domaine de l’odontologie, comme les anti-inflammatoires, les antibiotiques, les anesthésiques locaux ou encore les antiseptiques locaux ; 35,2 % sont des cas d’effets indésirables odontologiques comme les ostéonécroses de la mâchoire, les hypertrophies gingivales et les ulcérations buccales. Enfin, 28,3 % des cas concernent des déclarations d’effets indésirables en lien avec la vaccination <em>coronavirus disease</em> 2019 (COVID-19) débutée fin décembre 2020.</div></div><div><h3>Conclusion</h3><div>Le faible taux de déclarations de pharmacovigilance par les chirurgiens-dentistes en France au cours des dix dernières années met en évidence un problème de sous-déclaration des effets indésirables dans la pratique dentaire. Les données récentes de la littérature soulignent l’importance de la déclaration de pharmacovigilance dans le domaine de l’odontologie, notamment sur les effets odontologiques.</div></div><div><h3>Introduction</h3><div>Dentists, in their practice, bear responsibility for the benefits and the risks associated with the medications they prescribe. Their code of ethics grants them the freedom to prescribe while encouraging them to limit their interventions to what is strictly necessary for the quality and effectiveness of care. Furthermore, dentists also face ontological adverse effects resulting from medications they did not personally prescribe. A study based on the analysis of cases recorded over ten years in the national pharmacovigilance database (BNPV) is relevant for assessing the current state of pharmacovigilance reports submitted by dentists.</div></div><div><h3>Methods</h3><div>We conducted a retrospective analysis of the cases recorded in the BNP","PeriodicalId":23147,"journal":{"name":"Therapie","volume":"80 6","pages":"Pages 647-652"},"PeriodicalIF":1.8,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143721561","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
扫码关注我们
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号